Abbvie Biotechnology Ltd

Abbott Biotechnology Ltd.

Abbott Laboratories Corporation

Abbvie Inc.

George Avgerinos

Min M Wan

Gregory Zarbis-Papastoitsis

Tariq Ghayur

Zehra Kaymakcalan

Richard W Dixon

Albert Collinson

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

Purified antibody composition

The invention provides a method for producing a host cell protein&#x2014;(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1&#x3b1; and IL-1&#x3b2; and neutralize IL-1&#x3b1; and IL-1&#x3b2; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1&#x3b1; and IL-1&#x3b2;) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1&#x3b1; and/or IL-1&#x3b2; activity is detrimental.

Dual specificity antibodies and methods of making and using

Antibody purification

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1&#x3b1; and IL-1&#x3b2; and neutralize IL-1&#x3b1; and IL-1&#x3b2; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1&#x3b1; and IL-1&#x3b2; ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1&#x3b1; and/or IL-1&#x3b2; activity is detrimental.

Growing community of inventors

Sudbury, MA, United States of America

George Avgerinos